Related Experiment Video
Updated: Jul 9, 2025
Enhanced Genome Editing with Cas9 Ribonucleoprotein in Diverse Cells and Organisms
Published on: May 25, 2018
Highly efficient genome editing via CRISPR-Cas9 ribonucleoprotein (RNP) delivery in mesenchymal stem cells
A Reum Han1, Ha Rim Shin2, Jiyeon Kwon3
1Department of Translational Medicine and Department of Biochemistry and Molecular Biology, Asan Medical Institute of Convergence Science and Technology, Asan Medical Center, University of Ulsan College of Medicine, Seoul 05505; Stem Cell Immunomodulation Research Center, University of Ulsan College of Medicine, Seoul 05505, Korea.
Ribonucleoprotein (RNP) complexes offer superior genome engineering in mesenchymal stem cells (MSCs) compared to plasmid DNA. This optimized CRISPR-Cas9 RNP approach enhances MSC therapeutic potential by improving editing efficiency and reducing cytotoxicity.
Area of Science:
- Regenerative Medicine
- Stem Cell Biology
- Genome Engineering
Background:
- Mesenchymal stem cells (MSCs) are promising for regenerative medicine due to their differentiation and cytokine production capabilities.
- CRISPR-Cas9 technology facilitates genome editing in stem cells, but MSCs present challenges with inefficient editing and plasmid DNA sensitivity.
- Optimizing genome engineering strategies is crucial for advancing MSC-based therapeutics.
Discussion:
- This study compared plasmid DNA and Ribonucleoprotein (RNP) approaches for CRISPR-Cas9 mediated genome engineering in MSCs.
- The RNP approach demonstrated significantly higher indel frequencies and lower cytotoxicity in MSCs compared to plasmid DNA.
- Cas9 RNPs were successfully used to generate Beta-2-microglobulin (B2M)-knockout MSCs, enhancing their therapeutic properties.
Key Insights:
- RNP-mediated genome editing is highly efficient and minimally toxic in MSCs.
- B2M-knockout MSCs exhibit reduced T-cell differentiation and improved survival, indicating enhanced therapeutic potential.
- Engineered MSCs show augmented immunomodulatory effects, particularly after IFN-γ priming.
Outlook:
- The RNP approach represents a significant advancement for efficient MSC genome engineering.
- Engineered MSCs hold considerable promise as a next-generation therapeutic strategy in regenerative medicine.
- Further research into RNP-based engineering can unlock new possibilities for cell-based therapies.
